BioCentury | Feb 26, 2015
Distillery Therapeutics

Therapeutics: Not applicable

Neurology INDICATION: Parkinson's disease (PD) Rat studies suggest optogenetically mediated deep brain stimulation (DBS) utilizing complex, rather than simple, patterns could help treat PD-associated akinesia. In normal rats, electrophysiological testing recorded a signaling pattern that...
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Lipodystrophy Phosphate cytidylyltransferase 1 choline-a (PCYT1A) Biochemical and cell-based studies identified PCYT1A mutants that could be targeted to treat congenital lipodystrophies. Genetic sequencing and...
BioCentury | Nov 25, 2013
Clinical News

Vercise Deep Brain Stimulation regulatory update

Boston Scientific said it received CE Mark approval for its Vercise Deep Brain Stimulation (DBS) System to treat intractable primary and secondary dystonia. The Vercise DBS System, a neurostimulation device designed to deliver electrical signals...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Not applicable Rat studies suggest deep brain stimulation could be useful for promoting recovery of motor function...
BioCentury | Mar 21, 2011
Product Development

Location, location

Following the publication of full data from the first successful Phase II trial of a gene therapy candidate for Parkinson's disease, Neurologix Inc. believes it will be able to replace deep brain stimulation as the...
BioCentury | Jan 10, 2011
Company News

Boston Scientific, Intelect Medical deal

Boston Scientific acquired Intelect Medical for $60 million in cash. Intelect Medical is developing neuromodulation technologies for deep brain stimulation (DBS) therapy , including its Guide DBS programming system. Boston Scientific's Vercise DBS System, a neurostimulation...
BioCentury | Nov 15, 2010
Clinical News

Vercise Deep Brain Stimulation: Phase II started

Boston Scientific began the open-label, European Phase II VANTAGE trial to evaluate the Vercise DBS System in 40 patients. Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Product: Vercise Deep Brain Stimulation (DBS) System Business: Neurology Molecular...
Items per page:
1 - 7 of 7